

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE <b>41</b> Years	3. SEX <b>Female</b>	3a. WEIGHT <b>Unk</b>	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY  <input type="checkbox"/> OTHER
		Day	Month	Year				Day	Month	Year	
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>she could not sleep [Insomnia]</b> <b>nausea [Nausea]</b> <b>vomiting [Vomiting]</b> <b>had tremors in her hands [Tremor]</b>  Case Description: ***This is an auto generated narrative***  Study ID: 828652-My Healthy Journey  Study description: Trial title: This is a 40 weeks digital patient											

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL {Lot # PP5L468; Exp.Dt. JUN-2026}</b> (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) 1.8 mg, qd</b>	16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Subcutaneous</b>	
17. INDICATION(S) FOR USE <b>#1 ) for weight loss (Weight control)</b>		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) 02-MAY-2025 / Unknown</b>	19. THERAPY DURATION <b>#1 ) Unknown</b>	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)											
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) <table border="1"> <thead> <tr> <th>From/To Dates</th> <th>Type of History / Notes</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>Unknown to Ongoing</td> <td>Current Condition</td> <td>Overweight (Overweight)</td> </tr> <tr> <td>Unknown to Ongoing</td> <td>Current Condition</td> <td>Cyst (Cyst)</td> </tr> </tbody> </table>			From/To Dates	Type of History / Notes	Description	Unknown to Ongoing	Current Condition	Overweight (Overweight)	Unknown to Ongoing	Current Condition	Cyst (Cyst)
From/To Dates	Type of History / Notes	Description									
Unknown to Ongoing	Current Condition	Overweight (Overweight)									
Unknown to Ongoing	Current Condition	Cyst (Cyst)									

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888</b>		26. REMARKS <b>Medically Confirmed: No</b>
	24b. MFR CONTROL NO. <b>1438117</b>	25b. NAME AND ADDRESS OF REPORTER <b>NAME AND ADDRESS WITHHELD.</b>
24c. DATE RECEIVED BY MANUFACTURER <b>16-MAY-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>01-JUL-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

01-Jul-2025 07:05

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "she could not sleep(Sleep difficult)" beginning on 11-MAY-2025 , "nausea(Nausea)" beginning on 11-MAY-2025 , "vomiting(Vomiting)" beginning on 11-MAY-2025 , "had tremors in her hands(Tremor of hands)" beginning on 11-MAY-2025 and concerned a 41 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from 02-MAY-2025 and ongoing for "for weight loss",

Dosage Regimens:

Saxenda: 02-MAY-2025 to Not Reported, Not Reported to Not Reported (Dosage Regimen Ongoing);

Current Condition: Overweight, Cysts, Fibroids in the ovaries, Thyroid cysts.

Treatment medications included - ANTIMETIL(ZINGIBER OFFICINALE).

Batch Numbers:

Saxenda: PP5L468, PP5L468;

Action taken to Saxenda was reported as Dose Decreased.

On 13-MAY-2025 the outcome for the event "she could not sleep(Sleep difficult)" was Recovered.

On 13-MAY-2025 the outcome for the event "nausea(Nausea)" was Recovered.

On 13-MAY-2025 the outcome for the event "vomiting(Vomiting)" was Recovered.

On 13-MAY-2025 the outcome for the event "had tremors in her hands(Tremor of hands)" was Recovered.

Reporter's causality (Saxenda) -

she could not sleep(Sleep difficult) : Unknown

nausea(Nausea) : Unknown

vomiting(Vomiting) : Unknown

had tremors in her hands(Tremor of hands) : Unknown

Company's causality (Saxenda) -

she could not sleep(Sleep difficult) : Possible

nausea(Nausea) : Possible

vomiting(Vomiting) : Possible

had tremors in her hands(Tremor of hands) : Unlikely

**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL {Lot # PP5L468; Exp.Dt. JUN-2026}; Regimen #2	1.2 mg, qd (Dose decreased); Subcutaneous	for weight loss (Weight control)	Ongoing; Unknown

**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Fibroids (Uterine leiomyoma);
Unknown to Ongoing	Current Condition	Thyroid cyst (Thyroid cyst);